Actively Recruiting
Study of JWCAR201 Treatment for Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Led by Fudan University · Updated on 2024-07-24
9
Participants Needed
1
Research Sites
86 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and signals of effectiveness of JWCAR201, an autologous CD19CD20-directed CAR-T cell therapy, in adults with relapsed or refractory diffuse large B-cell lymphoma DLBCL. This open-label, single-arm study focuses on patients who have not responded to or have relapsed after at least two previous treatments, including standard therapies and stem-cell transplantation. The study uses a two-stage dose escalation design to find the safest and most effective dose. Participants will receive JWCAR201 after lymphocyte depletion with fludarabine and cyclophosphamide. The first stage uses an accelerated titration approach to increase doses until dose-limiting toxicities DLTs occur or a maximum dose is reached. The second stage uses a model-based method to determine the maximum tolerated dose MTD by evaluating the relationship between dose levels and toxicity risk. Dose levels explored include 25, 50, and 75 million CAR T cells, with backup doses for higher or lower levels. The study also examines pharmacokinetics and pharmacodynamics of JWCAR201. During the study, participants will be closely monitored for DLTs within 28 days and for adverse events over 24 months. Researchers will assess response rates, duration of response, progression-free survival, and overall survival. Blood samples will be collected to measure the JWCAR201 vector and specific immune cells. The study involves multiple visits and assessments over two years to evaluate safety, tolerability, and treatment effects in this patient population.
CONDITIONS
Brief Title
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Research Team
R
Rong Tao, MD
W
Wenhao Zhang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here